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Abstract
Background: TRAIL is a potent and specific inducer of apoptosis in tumour cells and therefore is a possible new
cancer treatment. It triggers apoptosis by binding to its cognate, death-inducing receptors, TRAIL-R1 and TRAIL-R2.
In order to increase its activity, receptor-specific ligands and agonistic antibodies have been developed and some
cancer types, including pancreatic cancer, have been reported to respond preferentially to TRAIL-R1 triggering. The
aim of the present study was to examine an array of TRAIL-receptor specific variants on a number of pancreatic
cancer cells and test the generality of the concept of TRAIL-R1 preference in these cells.
Methods: TRAIL-R1 and TRAIL-R2 specific sTRAIL variants were designed and tested on a number of pancreatic
cancer cells for their TRAIL-receptor preference. These sTRAIL variants were produced in HEK293 cells and were
secreted into the medium. After having measured and normalised the different sTRAIL variant concentrations, they
were applied to pancreatic and control cancer cells. Twenty-four hours later apoptosis was measured by DNA
hypodiploidy assays. Furthermore, the specificities of the sTRAIL variants were validated in HCT116 cells that were
silenced either for TRAIL-R1 or TRAIL-R2.
Results: Our results show that some pancreatic cancer cells use TRAIL-R1 to induce cell death, whereas other
pancreatic carcinoma cells such as AsPC-1 and BxPC-3 cells trigger apoptosis via TRAIL-R2. This observation extended
to cells that were naturally TRAIL-resistant and had to be sensitised by silencing of XIAP (Panc1 cells). The measurement
of TRAIL-receptor expression by FACS revealed no correlation between receptor preferences and the relative levels of
TRAIL-R1 and TRAIL-R2 on the cellular surface.
Conclusions: These results demonstrate that TRAIL-receptor preferences in pancreatic cancer cells are variable and that
predictions according to cancer type are difficult and that determining factors to inform the optimal TRAIL-based
treatments still have to be identified.
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Background
Pancreatic cancers are one of the most serious onco-
logical diseases, for which novel treatment options are
urgently needed. TRAIL is a cytokine that is involved in
natural tumour surveillance mechanisms and as recom-
binant protein has been shown to exert specific anti-
tumour effects by induction of apoptosis in cancer cells
[1–5]. Apoptosis is triggered after binding of TRAIL to
one of its two receptors, TRAIL-receptor 1 (TRAIL-R1)
or TRAIL-receptor 2 (TRAIL-R2), also known as DR4
and DR5, respectively [6–8]. Binding of TRAIL to these
two receptors stimulates the formation of a protein com-
plex called the death-inducing signaling complex (DISC).
It consists of TRAIL-R1 and/or TRAIL-R2, the adaptor
protein Fas-associated death domain (FADD) and
procaspase-8. At the DISC, caspase-8 is activated by a
mechanism that involves dimerisation and proteolytic
cleavage [9, 10]. Active caspase-8 can then, either dir-
ectly, or indirectly via the BH3-only protein Bid, activate
effector caspases, such as caspase-3, which in turn cleave
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many cellular substrates resulting in the biochemical
and morphological features characteristic of apoptosis
[11]. Aside from the two death domain (DD)-containing,
apoptosis-inducing receptors, TRAIL-R1 and TRAIL-R2,
three additional decoy receptors exist, TRAIL-R3
(DcR1), TRAIL-R4 (DcR2) and Osteoprogerin (OPG)
[6, 7, 12–14]. These decoy receptors can inhibit the
apoptosis-inducing function of TRAIL [15]. To address
this issue, agonistic antibodies against either TRAIL-R1 or
TRAIL-R2 have been developed and have been tested in
pre-clinical and as well as clinical studies [16–21].
In addition, engineered variants of TRAIL, containing
specific amino acid changes leading to specific targeting
of TRAIL-R1 or TRAIL-R2 have been designed and have
shown improved anti-tumour effects in-vitro and in-vivo
when compared to wild-type TRAIL [22–27]. Such
TRAIL-receptor variants have been studied in the con-
text of various specific cancer types as well as in the
context of combination treatments [28–32]. TRAIL vari-
ants might hold important advantages over TRAIL-
receptor specific antibodies as they are smaller than
antibodies and might therefore be better able to reach
and infiltrate growing tumours. In addition, such pro-
teins can be further optimised to increase activity, speci-
ficity and stability and they can be used as part of gene
and cell therapeutic approaches [31, 33–38]. This way of
potentially improving the therapeutic efficacy of TRAIL
by using TRAIL-receptor specific agents is of particular
interest for pancreatic cancer, as previous studies have
shown that pancreatic tumour cells preferentially use
TRAIL-R1 to execute TRAIL-induced apoptosis [39, 40].
Thus, agonistic TRAIL-R1 specific antibodies or TRAIL-
R1 targeting variants of TRAIL were regarded as having
a higher therapeutic potential than normal TRAIL in the
treatment of pancreatic carcinoma.
We wondered, given the molecular heterogeneity of
tumours, how such a uniform TRAIL response with re-
spect to receptor preferences could be possible. There-
fore, we set out to examine an array of pancreatic cancer
cells for their TRAIL-receptor preferences. We found
that a number of pancreatic cancer cells used TRAIL-R2
rather than TRAIL-R1 to initiate apoptosis signalling.
These results demonstrate that, while TRAIL-receptor
specific variants constitute a potentially substantial im-
provement to conventional TRAIL therapies, generalised
predictions according to cancer type are difficult. There-
fore, additional research is needed to identify factors that
determine the optimal TRAIL variant (or antibody) on a
case-by-case basis for each individual tumour.
Methods
Reagents and cell culture
All reagents were purchased from Sigma (St. Louis, MO)
unless otherwise stated. The human pancreatic cancer
cell lines Panc1 and PancTu1, the human embryonic
kidney cell line HEK293, the human colon cancer cell
line Colo205 and the human cervix carcinoma cell line
HeLa were maintained in Dulbecco’s modified Eagle’s
medium (DMEM). The human pancreatic cancer cell
lines AsPC-1, BxPC-3 and Colo357 were cultured in
RPMI-1640 medium. The human colorectal cancer cell
line HCT116 was cultured in McCoy’s medium and the
human prostate cancer PC-3 cells were grown in Ham’s
F12 medium. All media were supplemented with 10 %
FBS, 100 U/ml penicillin and 100 μg/ml streptomycin.
Cells were cultured in a humidified incubator at 37 °C
and 5 % CO2.
Generation of sTRAIL constructs
Generation of sTRAIL constructs and site-directed muta-
genesis have been previously described [31]. Briefly, the
soluble portion of human TRAIL (amino acids 114–281)
was first subcloned into the NheI/NotI sites of a pcDNA3
plasmid (Invitrogen) giving rise to pcDNA3.sTRAIL. Then
an exogenous signal peptide sequence of the human
fibrillin protein, the Furin cleavage site (Furin CS) and
Isoleucine-zipper sequence (ILZ) cassette was cloned
into the BamHI/NheI sites of the pcDNA3.sTRAIL vec-
tor. The resulting vector was termed sTRAILwt. The two
sTRAILDR5 and three sTRAILDR4 constructs were gen-
erated using the Quick-Change site-directed mutagen-
esis kit (Stratagene, La Jolla, CA) and confirmed by
DNA sequencing.
TRAIL Enzyme-linked Immunosorbent Assay (ELISA)
TRAIL concentrations were measured by a human
TRAIL/TNFSF10 Quantikine ELISA Kit as recommended
by the manufacturer (R&D Systems, Minneapolis, MN).
Before the measurement the medium supernatants were
pipetted off the respective HEK293 producer cells and
then centrifuged to clear them of any cellular debris.
TRAIL receptor surface stain
For the TRAIL receptor stain we used monoclonal anti-
TRAIL-R1 (DJR1) and anti-TRAIL-R2 (DJR2-4) anti-
bodies (1 μg/106 cells; BioLegend, San Diego, CA) that
were conjugated to Phycoerythrin (PE). The isotype con-
trol antibody (MOPC-21) (1 μg/106 cells) was also pur-
chased from BioLegend. The surface expression of
TRAIL receptors was measured by incubating cells with
the PE-conjugated mouse anti-human TRAIL-R1 and
mouse anti-human TRAIL-R2 antibodies as described
previously [41].
Transfection of HEK293 cells
HEK293 cells were transfected using the Calcium-
phosphate method. Briefly, before transfection, fresh 2 %
FBS containing medium was added to the cells. For each
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well of a 6-well plate, 0.5 ml HBS were aliquoted into a
sterile 1.5 ml Eppendorf tube. In a separate tube 5 μg of
plasmid DNA were mixed with 250 μl CaCl2 (2.5 mM)
and sterile water added to 0.5 ml. The CaCl2/DNA mix
was then added to the HBS in a drop-wise fashion and
constant vortexing at slow speed. After 45 min of incu-
bation at room temperature, the mixture was slowly
added to the cells. After 4 h, the medium was removed
and the cells were washed with PBS and fresh growth
medium added.
Apoptosis assay
Apoptosis was measured according to Nicoletti et al.
(DNA hypoploidy assay) and has been described
previously [42, 43]. Trypsinised cells including the super-
natant medium and PBS wash-solution were directly
transferred into FACS tubes and centrifuged at 1,300 rpm
for 7 min at 4 °C. After washing the cell pellet with PBS,
Nicoletti buffer (Sodium citrate 0.1 % (w/v) supplemented
with 0.1 % Triton X-100 (w/v) and propidium iodide at
50 μg/ml) was added. Then the tubes were vortexed for
10 s at medium speed and left for 5 h in a refrigerator.
The fluorescence intensity was then measured by flow cy-
tometry and analysed using the Venturi One software
package (Applied Cytometry, Sheffield, UK). Where speci-
fied, untreated cells were taken as reference to calculate
specific apoptosis by subtraction of the basal cell death
values from the apoptosis levels of treated cells.
RNAi knock-down constructs and stable cell line
generation
The following small hairpin (sh) RNA motifs were used
to silence: DR5 (5′-GCTAGAAGGTAATGCAGACTCT
GCCATGTC -3’), DR4 (5′-GCTGTTCTTTGACAAGT
TGC-3’) and XIAP (5′-GTGGTAGTCCTGTTTCAGC-3’).
Sense and antisense oligos containing the sh-sequence and
a 5’ overhang representing a restricted BbsI site and EcoRI
site on the 3’ side were hybridised to generate double-
stranded DNA fragments. These fragments were then
cloned into a BbsI/EcoRI opened up pU6.ENTR plas-
mid (Life Technologies, Carlsbad, CA). The resulting
pU6.ENTR plasmids (pU6.ENTR.shDR5, pU6.ENTR.shDR4,
pU6.ENTR.shXIAP) were used to generate the pBlock-
iT.shDR5, pBlock-iT.shDR4 and pBlock-iT.shXIAP
plasmids using the pBLOCK-iT6-DEST vector (Life
Technologies) and LR Clonase II. This was used to generate
stable DR5 and DR4 knock-down clones of HCT116 cells
and stable XIAP knock-down clones of PancTu1 and Panc1
cells. For this, the pBlock-iT.shDR5, pBlock-iT.shDR4 and
pBlock-iT.shXIAP plasmids were FuGeneHD-transfected
(Roche, Basle, Switzerland) into HCT116, PancTu1 and
Panc1 cells, respectively. Three days later, the trans-
fected cells were split into Blasticidin containing selec-
tion medium. Clones were then picked, transferred to
24 well-plates and analysed for DR5, DR4 and XIAP
knock-down, respectively. Clones that did not show a
knock-down were used as controls and labelled
PancTu1.shctrl and Panc1.shctrl, respectively. These
control clones were tested and shown to behave like
parental cells.
Statistical analysis
Experimental values are expressed as mean value ± stand-
ard error (SEM). For significance analyses, analysis of vari-
ance (ANOVA) between groups was used and P < 0.05 (*)
was considered significant.
Results
Expression and specificity of DR4- and DR5-specific TRAIL
variants
We used soluble TRAIL (sTRAIL) expression constructs
that we described previously [31, 36] to address the
TRAIL-receptor preference in pancreatic cancer. These
constructs contain an exogenous signal peptide sequence
from the human fibrillin-1 gene, a cleavage site for the
ubiquitous protease Furin, an Isoleucine Zipper domain
and the ectodomain of TRAIL (aa114-aa281). In addition
to the wild-type TRAIL construct (sTRAILwt), we engi-
neered constructs expressing three different DR4-specific
sTRAIL variants (termed sTRAILDR4–1, sTRAILDR4–2 and
sTRAILDR4–3) and two specific for DR5 (labelled
sTRAILDR5–1 and sTRAILDR5–2). These sTRAILDR4 and
sTRAILDR5 variants contained various amino acid changes
(Fig. 1a) [26, 44]. Following transfection of HEK293 cells
we could demonstrate that all TRAIL variants were
expressed and secreted to comparable levels (Fig. 1b).
TRAIL receptor specificity was confirmed in HCT116
cells silenced for TRAIL-R1 and TRAIL-R2, respectively.
We chose HCT116 cells, because of their relatively bal-
anced TRAIL-receptor preference and expression levels
(Fig. 1c). Cells with knocked-down TRAIL-R1 showed de-
creased apoptosis with all three sTRAILDR4 variants, but
elevated levels with sTRAILDR5 as compared to sTRAILwt
(Fig. 1d). In contrast, cells with silenced TRAIL-R2 exhib-
ited markedly reduced apoptosis in response to sTRAILDR5,
whereas the levels of cell death were increased with
the sTRAILDR4 variants, in particular with sTRAILDR4–3
(Fig. 1d). The likely reason for this observation is that in
TRAIL-R1 and TRAIL-R2 silenced cells the chance of
homotrimer formation is increased with sTRAIL variants
when compared to sTRAILwt and parental cells resulting
in higher apoptosis levels [24, 44].
Induction of apoptosis by TRAIL variants in pancreatic
cancer cells
Next, we tested several pancreatic cancer cells with the
array of TRAIL variants. In parallel, we analysed cancer
cells for which TRAIL-receptor preferences have been
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clearly documented, namely HeLa cells (TRAIL-R1) and
Colo205 cells (TRAIL-R2). Next, we applied the sTRAIL
variants to the pancreatic cancer cells Colo357, BxPC-3
and AsPC-1. After 24 h exposure to the sTRAIL variants
we measured apoptosis and found that HeLa (Fig. 2a)
and Colo205 (Fig. 2b) cells showed higher cell death
levels with sTRAILDR4 and sTRAILDR5, respectively.
However, while Colo357 pancreatic cancer cells exhib-
ited elevated cell death rates with sTRAILDR4 (Fig. 2c) as
reported previously [45], BxPC-3 (Fig. 2d) and AsPC-1
(Fig. 2e) cells responded with higher apoptosis levels to
sTRAILDR5.
TRAIL-receptor expression profile is not associated with
receptor preferences
Next, we analysed whether the observed preferences for
either TRAIL-R1 (HeLa, Colo357) or TRAIL-R2 (Colo205,
BxPC-3, AsPC-1) could be linked to the surface expression
levels of the two receptors. Using PE-conjugated antibodies
against TRAIL-R1 and TRAIL-R2 and the appropriate iso-
type control, we found that HeLa cells harboured robust
levels of TRAIL-R1 on their cell surface (MFI ratio:
4.12 +/− 0.05), whereas on Colo357 cells, we could
detect only comparably low levels of TRAIL-R1 (MFI
ratio: 2.51 +/− 0.43) (Fig. 3a). TRAIL-R2 levels in both
HeLa and Colo357 cells are slightly higher than
TRAIL-R1 (TRAIL-R2 MFI ratios: HeLa: 6.24 +/− 1.49
and Colo357: 3.42 +/− 0.55) (Fig. 3a). In the group of
cells that preferentially responded to sTRAILDR5 all
cells showed higher levels of TRAIL-R2 (MFI ratios:
Colo205: 7.33 +/− 0.14, AsPC-1: 10.42 +/− 2.43, BxPC-3:
4.54 +/− 0.75) than TRAIL-R1 (MFI ratios: Colo205: 2.90
+/− 0.04, AsPC-1: 4.02 +/− 0.96, BxPC-3: 2.31 +/− 0.55)
(Fig. 3b), with all of them expressing levels that are not
distinguishable from the group of cells reacting better to
sTRAILDR4. Thus, there is no straightforward correlation
between the levels of TRAIL-R1 and TRAIL-R2 and
TRAIL-receptor preference in TRAIL-induced apoptosis.
Fig. 1 Design, expression and specificity of sTRAIL specific variants. a Schematic drawing of sTRAIL constructs, all of which contain a heterologous
signal peptide sequence from the human fibrillin-1 gene (hFIB) ligated to a Furin cleavage site (Furin CS), an Isoleucine Zipper (ILZ) domain and
the soluble part of TRAIL (aa114-aa281). The expression was driven by a conventional CMV promoter/enhancer element (CMV). The mutations in
sTRAILwt leading to the two sTRAILDR5 (TRAIL-R2 specific) and three sTRAILDR4 (TRAIL-R1 specific) variants are shown in the respective sTRAIL
segments. b Results of ELISA analyses for TRAIL showing the levels of secreted sTRAILwt (yellow), sTRAILDR5–1 (dark green), sTRAILDR5–2 (light
green), sTRAILDR4–1 (dark blue), sTRAILDR4–2 (light blue) and sTRAILDR4–3 (blue-grey) into the supernatant of HEK293 cells that were transfected with
the described constructs. Results for cells transfected with an EGFP control expression construct (ctrl; grey) are also shown. c FACS histogram of
HCT116 cells showing membrane expression levels of TRAIL-R1 (red) and TRAIL-R2 (blue). The FACS profile of the isotype control is shown as filled
black. d Supernatants from HEK293 cells transfected with either an EGFP control expression plasmid (grey), sTRAILwt (yellow), sTRAILDR5–1 (dark
green), sTRAILDR5–2 (light green), sTRAILDR4–1 (dark blue), sTRAILDR4–2 (light blue) or sTRAILDR4–3 (blue-grey) were normalised to 2 ng/ml TRAIL (the
EGFP control was diluted 1:2 in fresh medium) and then applied to HCT116 (left), HCT.shDR4 (centre) and HCT.shDR5 cells (right), respectively,
before apoptosis was measured 24 h later
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Induction of apoptosis in sensitised TRAIL resistant
pancreatic cancer cells
It is well known that some pancreatic cancer cells are re-
sistant to TRAIL (Fig. 4a). Therefore, in order to examine
the TRAIL receptor preference in such cells, we silenced
the anti-apoptotic protein XIAP in PancTu1 (PancTu1.sh-
XIAP) and Panc1 (Panc1.shXIAP) cells and treated them
with sTRAIL variants. The results show that knocking
down of XIAP sensitised the cells to TRAIL-induced
apoptosis, with sTRAILDR4 having a significantly better ef-
fect in PancTu1.shXIAP (Fig. 4b), as previously described,
but sTRAILDR5 leading to more apoptosis in Panc1.sh-
XIAP (Fig. 4c). Thus not all pancreatic cancer cells possess
a preference for the TRAIL-R1 apoptosis pathway as re-
ported previously [39, 40]. Instead, a group of pancreatic
cancer cells have a higher propensity to undergo TRAIL-
induced apoptosis via TRAIL-R2.
TRAIL-receptor expression profile is not associated with
receptor preferences in XIAP-silenced pancreatic cancer cells
Next, we also measured TRAIL-R1 and TRAIL-R2 ex-
pression on the surface of both Panc1.shctrl and
PancTu1.shctrl cells as well as their XIAP-silenced coun-
terparts, Panc1.shXIAP and PancTu1.shXIAP cells. We
found that the profiles of TRAIL-receptor expression
did not differ between the control cells (Panc1.shctrl and
PancTu1.shctrl) and the corresponding XIAP knock-
down clones (Panc1.shXIAP and PancTu1.shXIAP)
(Fig. 5a and b). TRAIL-R1 expression was almost un-
detectable in Panc1.shctrl and Panc1.shXIAP (MFI ra-
tios: Panc1.shctrl: 1.81 +/− 0.44 and Panc1.shXIAP:
1.74 +/− 0.30), whereas TRAIL-R2 expression was
readily detectable (MFI ratios: Panc1.shctrl: 3.33 +/−
0.57 and Panc1.shXIAP: 3.2 +/− 0.60). In Panc-
Tu1.shctrl and PancTu1.shXIAP both TRAIL-R1 and
TRAIL-R2 were expressed at robust levels (TRAIL-R1
MFI ratios: PancTu1.shctrl: 3.15 +/− 0.17 and Panc-
Tu1.shXIAP: 2.52 +/− 0.10; TRAIL-R2 MFI ratios:
PancTu1.shctrl: 5.67 +/− 0.13 and PancTu1.shXIAP:
5.90 +/− 0.08). This comparison of TRAIL-receptor
levels in TRAIL resistant pancreatic cells also does not
show a clear correlation between TRAIL-receptor ex-
pression levels and TRAIL-receptor preference after
XIAP sensitisation.
Fig. 2 The TRAIL receptor preference for apoptosis induction is variable in pancreatic cancer cells. a-e Supernatants from HEK293 cells that were
transfected with the EGFP control expression construct (ctrl; grey; 1:2 diluted), sTRAILwt (yellow; 2 ng/ml), sTRAILDR5–1 (dark green; 2 ng/ml),
sTRAILDR5–2 (light green; 2 ng/ml), sTRAILDR4–1 (dark blue; 2 ng/ml), sTRAILDR4–2 (light blue; 2 ng/ml) or sTRAILDR4–3 (blue-grey; 2 ng/ml) were then
transferred onto (a) HeLa cells (prototypic DR4 specific cell type), (b) Colo205 cells (prototypic DR5 specific cell type), (c) Colo357 pancreatic
cancer cells, (d) BxPC-3 pancreatic cancer cells and (e) AsPC-1 pancreatic cancer cells. After 24 h apoptosis was measured
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Discussion
Initially it was thought that TRAIL-R2 is the main
apoptosis-inducing receptor for the death ligand TRAIL
[27]. This led to the development and testing of
agonistic antibodies against this receptor as potential
anti-cancer agents [16, 18, 46, 47]. However, more re-
cently reports showed that TRAIL-R1 has a more prom-
inent role, than first thought, in specific types of cancer
Fig. 3 TRAIL-receptor surface expression profiles of pancreatic cancer cells and control cell lines. a FACS histograms of HeLa and Colo357 cells
showing membrane expression levels of TRAIL-R1 (black) and TRAIL-R2 (red). The FACS profile of the isotype control is shown as filled grey.
b FACS histograms of Colo205, AsPC-1 and BxPC-3 cells showing membrane expression levels of TRAIL-R1 (black) and TRAIL-R2 (red). The FACS
profile of the isotype control is shown as filled grey. c Quantification of the FACS results for TRAIL-R1 (black) and TRAIL-R2 (red) for HeLa, Colo357,
Colo205, AsPC-1 and BxPC-3 cells. The surface expression levels of the two receptors are expressed as MFI ratios
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such as lymphoid malignancies [29] and leukaemic cells
[30, 48]. Additionally, it was suggested that pancreatic
cancer cells also trigger TRAIL-induced apoptosis
mainly through TRAIL-R1 [39, 40]. However, when we
analysed a wider array of pancreatic cancer cell lines we
found that 2 out of 3 pancreatic cancer cells preferred
the TRAIL-R2 pathway in response to TRAIL. In
addition, Panc1 cells also showed higher apoptosis levels
when treated with sTRAILDR5 and XIAP was silenced
concomitantly (Table 1).
While these results appear to contrast the two afore
mentioned publications [39, 40], it is important to point
out that we used, at least in part, different cell lines and
sTRAIL variant proteins instead of agonistic antibodies.
Interestingly, the results in one of the reports indicate
that both TRAIL-R1 and TRAIL-R2 agonistic antibodies
can trigger apoptosis in pancreatic cells and that the
TRAIL-R1 preference was only detected when one of
the two receptors was inhibited by blocking antibodies
followed by treatment with TRAIL [39]. In contrast, the
second study found clear differences between the
apoptosis-inducing activities of the two agonistic anti-
bodies, with a clear preference for TRAIL-R1. It is there-
fore possible that sTRAIL variant proteins and TRAIL-
receptor specific antibodies have distinct effects owing
to their different modes of action with regard to their
Fig. 4 TRAIL receptor preference is also variable in apoptosis-sensitised pancreatic cancer cells. a TRAIL-sensitive control cells (PC-3), Panc1, Panc1.shctrl,
PancTu1 and PancTu1.shctrl were treated with 10 ng/ml rTRAIL for 24 h, before apoptosis was measured. b PancTu1.shXIAP cells were treated with
supernatants from HEK293 cells that were transfected with the EGFP control expression construct (ctrl; grey), sTRAILwt (yellow), sTRAILDR5–2 (light green)
or sTRAILDR4–3 (blue-grey). After 24 h apoptosis was measured. c Panc1.shXIAP cells were treated with supernatants from HEK293 cells that were
transfected with the EGFP control expression construct (ctrl; grey), sTRAILwt (yellow), sTRAILDR5–2 (light green) or sTRAILDR4–3 (blue-grey). After 24 h
apoptosis was measured
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Fig. 5 TRAIL-receptor surface expression profiles of TRAIL resistant pancreatic cancer cells and their XIAP silenced counterparts. a FACS
histograms of Panc1.shctrl and Panc1.shXIAP cells showing membrane expression levels of TRAIL-R1 (black) and TRAIL-R2 (red). The FACS profile
of the isotype control is shown as filled grey. b FACS histograms of PancTu1.shctrl and PancTu1.shXIAP cells showing membrane expression levels
of TRAIL-R1 (black) and TRAIL-R2 (red). The FACS profile of the isotype control is shown as filled grey. c Quantification of the FACS results for
TRAIL-R1 (black) and TRAIL-R2 (red) for Panc1.shctrl, Panc1.shXIAP, PancTu1.shctrl and PancTu1.shXIAP cells. The surface expression levels of the
two receptors are expressed as MFI ratios
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receptor engagement. Notwithstanding, the notion that
pancreatic cancer cells and possibly other tumour types
have a general TRAIL receptor preference needs to be
re-visited, re-examined and possibly refined. Further-
more, we tested whether the expression profile of
TRAIL-R1 and TRAIL-R2 could determine receptor
preference, but failed to observe any clear correlation.
These findings are generally in line with results reported
earlier [39]. Thus, other factors and mechanisms than
surface expression levels of the TRAIL-receptors must
determine their apoptosis-inducing function.
Potential molecular mechanisms that could determine
whether a receptor can be activated are O-glycosylation
of both receptors [49] as well as S-palmitoylation, S-
nitrosylation, N-glycosylation and ubiquitination of
TRAIL-R1 [50–53]. Thus, despite being present on the
cell surface a receptor might be relatively inactive,
making it impossible to determine receptor prefer-
ences based solely on expression levels.
An area where specific TRAIL variants and/or agonis-
tic antibodies can be used with good predictability is in
combination treatments, in which up-regulation of
either TRAIL-R1 or TRAIL-R2 can be targeted by the
respective variant. For example, pre-treatment with the
anti-cancer drug doxorubicin gave rise to significantly
increased cell death when treated with the agonistic
TRAIL-R2 antibody lexatumumab [54]. In addition,
combined treatment of colorectal tumours with lexatu-
mumab and radiotherapy had similar sensitising effects
[55]. Soluble TRAILDR5 also showed better apoptosis
inducing effects after priming with 5-Fluorouracil as
compared to sTRAILwt or sTRAILDR4, because the drug
caused p53-independent upregulation of TRAIL-R2 [31].
In contrast, HDAC inhibition has been shown to result
in sensitisation to TRAIL-R1 specific apoptosis [48, 56].
Of note in this context is that the individual activa-
tion of TRAIL-R1 and -R2 could be an advantage,
since it was shown that combined exposure to
DR4- and DR5-selective TRAIL variants in cells,
sensitive for both receptors, was more potent in
triggering apoptosis when compared to single agent
treatment [22]. Other factors that can influence TRAIL re-
ceptor preferences are so called non-canonical pathways
including the activation of NF-κB, p38 and JNK [57]. The
issue with these pathways is that they have been reported
to have opposing effects and different apoptosis factor re-
quirements depending on cell type and cellular context
[57]. For example, TRAIL-induced JNK activation has
been reported to be caspase-dependent in HeLa human
cervical cancer cells, but caspase-independent in the hu-
man rhabdomyosarcoma Kym-1 cell line [58]. These find-
ings illustrate that the TRAIL receptors have varying, cell
type-specific and in parts receptor specific capabilities to
recruit different signalling complexes to their intracellular
domain. These complexes and their individual constitu-
ents might have an impact on the apoptosis-inducing
function of the receptors and thereby may contribute to
TRAIL-receptor preferences in TRAIL-triggered cell
death.
Consequently, further research is needed to better
understand potential differences between TRAIL agonis-
tic antibodies and recombinant TRAIL proteins and
variants. Additionally, it is important to elucidate the
molecular components that determine TRAIL-receptor
preferences in order to be able to select the best TRAIL
agents to potentially treat pancreatic cancer and other
tumour types in the future.
Conclusions
We discovered that not all pancreatic cancer cells favour
the TRAIL-R1 pathway to induce apoptosis and that
no clear and direct correlation exists between the sur-
face expression levels of TRAIL-R1 and TRAIL-R2 and
their preference for one of the two receptors. AsPC-1,
BxPC-3 and Panc1 cells elicit apoptosis via TRAIL-R2,
whereas Colo357 cells and PancTu1 cells preferred
TRAIL-R1 to induce cell death. Thus, claims of general
cancer type specific TRAIL receptor preference should
be taken with a pinch of salt.
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